A corneal device comprising a base surface and a top surface, and having a water content ranging from about 78%-92% (w/w), inclusive. The corneal device can be used to treat, for example without limitation, ectatic corneal disease by supporting corneal structure weakened by the disease and/or changing an anterior curvature of the cornea.

A corneal device comprising a base surface and a top surface, and having a water content ranging from about 78%-92% (w/w), inclusive. The corneal device can be used to treat, for example without limitation, ectatic corneal disease by supporting corneal structure weakened by the disease and/or changing an anterior curvature of the cornea.

The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.

The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.

A biomedical device is disclosed. The biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more non-silicone biomedical device-forming monomers.

A biomedical device is disclosed. The biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more non-silicone biomedical device-forming monomers.

Disclosed herein is a hybrid polymeric material comprising a tropoelastin and a copolymer of a polyol monomer and a polycarboxylic acid monomer. The hybrid polymeric material is suitable for use as a tissue scaffold.

Disclosed herein is a hybrid polymeric material comprising a tropoelastin and a copolymer of a polyol monomer and a polycarboxylic acid monomer. The hybrid polymeric material is suitable for use as a tissue scaffold.

Disclosed herein is a hybrid polymeric material comprising a tropoelastin and a copolymer of a polyol monomer and a polycarboxylic acid monomer. The hybrid polymeric material is suitable for use as a tissue scaffold.

The present invention relates to a medical composition and a method for preparing the same, the medical composition comprising: an adipose tissue-derived extracellular matrix powder; and a biocompatible polymer or a crosslinked product of the biocompatible polymer. The medical composition according to the present invention exists in a well-aggregated state even after implantation in the body and can maintain the volume thereof for a certain time.